GB202108245D0 - Methods of treatment - Google Patents

Methods of treatment

Info

Publication number
GB202108245D0
GB202108245D0 GBGB2108245.8A GB202108245A GB202108245D0 GB 202108245 D0 GB202108245 D0 GB 202108245D0 GB 202108245 A GB202108245 A GB 202108245A GB 202108245 D0 GB202108245 D0 GB 202108245D0
Authority
GB
United Kingdom
Prior art keywords
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2108245.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionctura SA
Original Assignee
Ionctura SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionctura SA filed Critical Ionctura SA
Priority to GBGB2108245.8A priority Critical patent/GB202108245D0/en
Publication of GB202108245D0 publication Critical patent/GB202108245D0/en
Priority to CN202280032188.0A priority patent/CN117295496A/zh
Priority to JP2023574275A priority patent/JP2024522135A/ja
Priority to PCT/EP2022/065562 priority patent/WO2022258693A1/en
Priority to AU2022290378A priority patent/AU2022290378B2/en
Priority to MX2023014637A priority patent/MX2023014637A/es
Priority to EP22734239.1A priority patent/EP4351563A1/en
Priority to CA3218103A priority patent/CA3218103A1/en
Priority to US18/567,932 priority patent/US20250057820A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB2108245.8A 2021-06-09 2021-06-09 Methods of treatment Ceased GB202108245D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB2108245.8A GB202108245D0 (en) 2021-06-09 2021-06-09 Methods of treatment
CN202280032188.0A CN117295496A (zh) 2021-06-09 2022-06-08 用于治疗胰腺癌的自分泌运动因子(atx)抑制剂
JP2023574275A JP2024522135A (ja) 2021-06-09 2022-06-08 膵臓癌の治療のためのオートタキシン（ａｔｘ）阻害剤
PCT/EP2022/065562 WO2022258693A1 (en) 2021-06-09 2022-06-08 Autotaxin (atx) inhibitor for the treatment of pancreatic cancer
AU2022290378A AU2022290378B2 (en) 2021-06-09 2022-06-08 Autotaxin (atx) inhibitor for the treatment of pancreatic cancer
MX2023014637A MX2023014637A (es) 2021-06-09 2022-06-08 Inhibidor de autotaxina (atx) para el tratamiento del cancer de pancreas.
EP22734239.1A EP4351563A1 (en) 2021-06-09 2022-06-08 Autotaxin (atx) inhibitor for the treatment of pancreatic cancer
CA3218103A CA3218103A1 (en) 2021-06-09 2022-06-08 Autotaxin (atx) inhibitor for the treatment of pancreatic cancer
US18/567,932 US20250057820A1 (en) 2021-06-09 2022-06-08 Autotaxin (atx) inhibitor for the treatment of pancreatic cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2108245.8A GB202108245D0 (en) 2021-06-09 2021-06-09 Methods of treatment

Publications (1)

Publication Number Publication Date
GB202108245D0 true GB202108245D0 (en) 2021-07-21

Family

ID=76838834

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2108245.8A Ceased GB202108245D0 (en) 2021-06-09 2021-06-09 Methods of treatment

Country Status (9)

Country Link
US (1) US20250057820A1 (enExample)
EP (1) EP4351563A1 (enExample)
JP (1) JP2024522135A (enExample)
CN (1) CN117295496A (enExample)
AU (1) AU2022290378B2 (enExample)
CA (1) CA3218103A1 (enExample)
GB (1) GB202108245D0 (enExample)
MX (1) MX2023014637A (enExample)
WO (1) WO2022258693A1 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9850203B2 (en) * 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds
GB201502020D0 (en) * 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
JP2024511836A (ja) * 2021-03-29 2024-03-15 アイオンクチュラ・ソシエテ・アノニム 膵臓癌の治療のためのｐｉ３ｋ－デルタ阻害剤

Also Published As

Publication number Publication date
AU2022290378A1 (en) 2024-01-04
AU2022290378B2 (en) 2026-06-11
WO2022258693A1 (en) 2022-12-15
EP4351563A1 (en) 2024-04-17
MX2023014637A (es) 2024-01-31
JP2024522135A (ja) 2024-06-11
CA3218103A1 (en) 2022-12-15
US20250057820A1 (en) 2025-02-20
CN117295496A (zh) 2023-12-26

Similar Documents

Publication Publication Date Title
GB202020573D0 (en) Novel methods of therapy
IL315503A (en) Treatment methods
IL290983A (en) Treatment methods
GB202020572D0 (en) Novel methods of therapy
IL320711A (en) Treatment methods
IL287250A (en) treatment method
GB202201824D0 (en) Methods of treatment
GB201918853D0 (en) Methods of treatment
GB202201819D0 (en) Methods of treatment
GB202201825D0 (en) Methods of treatment
IL312155A (en) A method for treating cancer
IL290853A (en) Treatment methods using omelizumab
GB202118006D0 (en) Methods of treatment
GB202118007D0 (en) Methods of treatment
GB202118011D0 (en) Methods of treatment
GB202108242D0 (en) Methods of treatment
GB202005874D0 (en) Methods of treatment
IL268111A (en) Methods of treating pain
IL325944A (en) Methods of treatment
GB202102950D0 (en) Method of treatment
GB202018243D0 (en) Method of treatment
GB202012436D0 (en) Method of treatment
GB202006739D0 (en) Method of treatment
GB202005015D0 (en) Method of treatment
GB202101251D0 (en) Treatment of conditions

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)